Medical News, Journals & Upcoming Events
Latest Hematology / Oncology Articles
- Prescription without Precision — Dangers of Dosing on the Basis of Race as Biology June 11, 2026Despite recognition that racial and ethnic categories are poor proxies for genetic diversity, race is still used to guide pharmaceutical use, posing risks of ineffectively low or dangerously high dosing.Harsimar K. Ahuja, David S. Jones, Winfred W. Williams
- Antidotes for Anticoagulation Reversal June 11, 2026The authors review current strategies for anticoagulation reversal in major bleeding events or urgent surgery as well as specific antidotes, limits of available evidence, thrombotic risks, unmet therapeutic needs, and ongoing research.Bianca Rocca, Hugo ten Cate
- Osteosarcoma June 11, 2026An 11-year-old girl presented with a 1-month history of right thigh pain that worsened at night. Radiographs of the knee revealed a metaphyseal osteoblastic lesion with a sunburst appearance.Hsueh-Min Kuo, Wei-Ming Chen
Latest Allergy & Immunology Articles
- Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation June 11, 2026The authors describe the scientific foundations of a study implicating autoantibodies against interleukin-10 in persons with inflammatory bowel disease.Paul Bastard, Jean-Laurent Casanova
- Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease June 11, 2026Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele.Nima Gharahdaghi, Pai-Jui Yeh, Lourdes Ceron-Gutierrez, Helen Griffin, Hannah Gordon, Chamara Jayamanne, Alice Fracchia, Amanda Y. Chong, Alissa Walsh, Oliver Brain, Katherine Baker, Hannah Kockelbergh, Yang Luo, Martha Guevara Becerra, Katherine Vadakethala, Madeleine Coy, Ladan Kabiri, Martin Barnardo, Susanna Dunachie, Barbara Kronsteiner, Anna Adams, Darren Fowler, Qian Zhang, Laura Fachal, Carl A. Anderson, Rofaida Desoki, Marie Vibeke Vestergaard, Lone Larsen, Nicola J. Wyatt, Robert D. Lees, Robert J. Mulligan, Chaonan Dong, Mohmmed Tauseef Sharip, Siân E. Faustini, Adrian Shields, Julia Pakpoor, Bushra Naz, Alex Richter, Jack Satsangi, Christopher A. Lamb, Miles Parkes, Fiona Powrie, Alexander J. Mentzer, Aleksejs Sazonovs, Tine Jess, Paul Klenerman, Simon Travis, Sophie Hambleton, Rainer Doffinger, Holm H. Uhlig
- Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy June 5, 2026In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission.Fernando C. Fervenza, Fan Fan Hou, Chuan-Ming Hao, Gianna M. Kirsztajn, Loreto Gesualdo, Tomasz Hryszko, Antonio Pisani, Dario Roccatello, Andrew S. Bomback, Julie Rae, Farima Barmaki, Eriola Berisha, Thomas Schindler, Theodore A. Omachi, Jay P. Garg, Ana Malvar, the MAJESTY Trial Investigators*
To receive information about upcoming events and the latest CE Activities, join our network.
